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Abstract: Bioadhesive nanoparticles have been proposed as carriers for the oral delivery 
of poorly available drugs and facilitate the use of this route. This work summarises some 
experiments describing the bioadhesive potential of Gantrez nanoparticles fluorescently 
labeled with rhodamine B isothiocyanate. The adhesive potential of Gantrez was found to 
be stronger when folded as nanoparticles than in the solubilised form. Conventional 
nanoparticles displayed a tropism for the upper areas of the gastrointestinal tract, with a 
maximum of adhesion 30 min post-administration and a decrease in the adhered fraction 
along the time depending on the given dose. The cross-linkage of nanoparticles with 
increasing amounts of 1,3-diaminopropane stabilised the resulting carriers and prolonged 
their half-life in an aqueous environment; although, the adhesive capacity of 
nanoparticles, the intensity and the relative duration of the adhesive interactions within 
the gut as a function of the cross-linking degree. Finally, nanoparticles were coated with 
either gelatin or albumin. In the first case, the presence of gelatin dramatically decreased 
the initial capacity of these carriers to interact with the gut mucosa and the intensity of 
these phenomenons. In the latter, bovine serum albumin coated nanoparticles (BSA-NP) 
showed an important tropism for the stomach mucosa without further significant 
distribution to other parts of the gut mucosa. 
Keywords: nanoparticles, bioadhesion, Gantrez, oral administration. 
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Introduction 
 
The oral route is one of the preferred ways for drug delivery. However, a large amount of drugs 
remain poorly available when administered by this route. Among other reasons, this fact can be related 
to: (i) a low mucosal permeability for the given drug (usually observed for hydrophilic drugs); (ii) a 
low solubility or a low dissolution rate in the mucosal fluids, which results in its elimination from the 
alimentary canal prior to absorption (quite common for lipophilic drugs); (iii) a drug permeability 
restricted to a region of the gut (drugs with an absorption window) or (iv), a lack of stability within the 
gut (i.e. oligonucleotides, peptides and plasmids). 
One possible strategy to overcome or minimise these drawbacks and, thus, improve drug 
absorption or action may be the use of biodegradable nanoparticles with bioadhesive properties. 
Nanoparticles are solid colloidal particles ranging in size from about 10 to 1000 nm [1]. Depending on 
the method of preparation, nanospheres or nanocapsules can be obtained. Nanocapsules are vesicular 
systems in which the drug is confined to a cavity surrounded by a unique polymer membrane, while 
nanospheres are matrix systems in which the drug is physically and uniformly dispersed [2].  
Drugs, whose oral bioavailability was improved by means of their loading into these carriers 
include vincamine [3], insulin [4, 5], salmon calcitonin [6], furosemide [7], avarol [8], dicumarol [9], 
nifedipine [10], plasmids [11, 12] and 5-fluorouridine [13]. 
When a suspension of nanoparticles is administered by the oral route, the particles may interact 
with the gastrointestinal surface and develop adhesive bonds with different components of the mucosa. 
These nanoparticles would be immobilised at the gastrointestinal surface by an adhesion mechanism, 
which is referred to as “bioadhesion”. However, when these adhesive interactions are restricted to the 
mucus layer lining the mucosal surface, the term “mucoadhesion” is also employed. All of these 
adhesive phenomena may result in either: (i) an increase of the residence time of the pharmaceutical 
dosage form in close contact with the mucosa, or (ii) a localization of the delivery system in a 
particular region of the gut (Figure 1).  
Figure 1. Illustration representing the interaction of nanoparticles with the gut mucosa. 
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Once adhered to the gut mucosa, these carriers would promote the absorption of the given drug and 
its transport to the systemic circulation by a multiple mechanism involving protection of the loaded 
drug against degradation and establishment of a drug concentration gradient from the drug carrier 
(nanoparticle) towards the absorptive membrane. 
The first reported study, concerning the description of the bioadhesive properties of nanoparticles, 
was described by the oral administration of radiolabelled poly(hexyl cyanoacrylate) nanoparticles to 
mice. The whole-body autoradiography showed that, 30 min after the oral administration of these 
nanoparticles, they were exclusively localized in the stomach. After 4 h, a large quantity of 
radioactivity was found in the intestine in the form of clusters without any evidence of accumulation at 
specific intestinal sites [14, 15]. Also a mucoadhesion profile was described after intragastric 
administration of micron-range 14C radiolabelled poly(lactic acid) microspheres to rats [16]. The time 
necessary for the detachment of half of the adherent particles has been estimated to be 1.4 h [16]. This 
value is in the range of the estimated time for complete renewal of the intestinal mucus gel layer. In 
fact, the turnover time of the intestinal mucus layer is in the order of 90-240 min [17]. This rapid 
renewal also results in the formation of shed-off mucus in the luminal content. All together, lead to a 
reduction of the contact time of the particles with the mucus layer.  
However, the intensity of the adhesive interactions with the mucosa and the fraction of the particles 
able to adhere to the biological surface appear to be mainly dependent on the physico-chemical 
properties of the colloidal drug delivery system. Among other properties, the particle size and the 
surface characteristics of the carriers strongly modulate the transit and adhesion within the 
gastrointestinal tract.  
Particle size is a critical parameter that will ultimately control diffusion through the mucus gel 
layer. In principle, a small particle size may dramatically prolong the residence time of the 
pharmaceutical dosage form in the gastrointestinal tract, due to an important decrease on the influence 
of the intestinal clearance mechanisms and the high increase on the specific surface able to interact 
with the biological support [18]. Studies using cystic fibrosis sputum demonstrated that the largest 
spheres studied, of 560 nm diameter were almost completely blocked, while 124 nm nanoparticles 
were able to permeate this barrier [19]. In the gastrointestinal tract, a number of investigators have 
shown the translocation of much larger particles [20-22]. According to these results, there is a size 
exclusion phenomenon on the absorption of particulates through the intestinal wall. It is suggested that 
small (submicron) particles are absorbed and transported via the intracellular or paracellular pathway 
through the enterocytes, while larger particles (micron range) are absorbed almost exclusively by M 
cells of Peyer’s patches [23, 24]. The phenomenon of particulate movement through the mucus layer 
has possibly been studied most intensively in relation to bacterial movement particularly by the 
pioneering works of Freter et al. [25] and Berg [26] who have, respectively, shown over the past two 
decades the movement of micron sized latex particles through the mucus and into mesentery lymph 
nodes in mice.  
In the last years the research of new biomaterials for the preparation of nanoparticles has reached a 
great interest. Ideally, the material used to prepare the drug carrier has to be able to carry and control 
the release of the loaded drug and, also, it has to possess functional groups to modify or decorate the 
surface of nanoparticles. This last characteristic is the key point to design new nanoparticles with 
specific distribution within the mucosa. All of these prerequisites limit the number of polymers and 
macromolecules, which can be used to prepare nanoparticles with bioadhesive properties. 
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Recently, the copolymer between methyl vinyl ether and maleic anhydride (PVM/MA; Figure 2) 
has been proposed as a new material to prepare bioadhesive nanoparticles for oral drug delivery [27]. 
The different copolymers (commercialised as Gantrez from ISP, USA), are widely employed for 
pharmaceutical applications as denture adhesives, thickening and suspending agents and as adjuvants 
for the preparation of transdermal patches. In addition the ester derivatives are also employed as film-
coating agents.  The oral toxicity of all of these polymers are quite low (i.e. for Gantrez® AN the LD50 
in guinea pigs is about 8-9 g/kg per os).  
 
Figure 2. Chemical structure of Gantrez AN or poly(methylvinylether-co-maleic anhydride). 
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Preparation and characterization of Gantrez nanoparticles 
 
PVM/MA nanoparticles were prepared by a solvent displacement method [27]. For this purpose the 
copolymer (Gantrez AN 119) was dissolved in acetone and desolvated by the addition of a 
hydroalcoholic phase under magnetic stirring. The organic solvents were eliminated under reduced 
pressure and the resulting aqueous suspension of nanoparticles was purified by centrifugation and 
lyophilised using sucrose as cryoprotector (Figure 3).  
In aqueous medium, these nanoparticles (NP) can be dissolved quite rapid. In fact, their complete 
dissolution in pure water takes less than 24 h. In order to increase their stability in biological mediums, 
one possibility consist on the cross-linkage of these carriers. For this purpose, the freshly prepared 
nanoparticles were hardened by incubation at room temperature for 5 min with increasing amounts of 
1,3-diaminopropane (from 5 to 30 µg/mg bulk polymer), before purification and lyophilisation. These 
nanoparticles were called DP5-NP, DP10-NP and DP30-NP.  
On the other hand, in an aqueous environment, this copolymer can also easily react with molecules 
containing amino residues. This property was used to coat these nanoparticles. For this purpose, the 
just prepared carriers were incubated for 2 h at room temperature with either bovine serum albumin 
(BSA) or gelatin (G). Then the coated nanoparticles (BSA-NP and G-NP) were purified by 
centrifugation and freeze-dried as described before. For in vivo experiments, all the nanoparticle 
batches were fluorescently labelled with rhodamine B isothiocyanate (RBITC).  This marker was 
added before the purification step as shown the scheme of Figure 3.  
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Figure 3.  Illustration of the preparative process of Gantrez AN nanoparticles. The drug 
(or the fluorescent marker) can be added in different steps of the process. 
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Table 1 summarises the main physico-chemical characteristics of the different nanoparticles tested 
in this study. In all cases, the yield of the described process was calculated to be of about 73.8±2.6 % 
of the copolymer transformed into nanoparticles.  
 
Table 1. Physico-chemical characteristics of Gantrez nanoparticles (n=6). NP: 
conventional nanoparticles; D5-NP, D10-NP and D30-NP: cross-
linked nanoparticles with DP; Gantrez-sol: aqueous solution of the 
copolymer which was obtained after the complete dissolution of NP 
in water. 
 
 Size 
(nm) 
Zeta potential 
(mV) 
RBITC content  
(µg/mg) 
Protein bound 
µg/mg) 
Gantrez-sol - - 9.95 ± 0.45 - 
NP 279 ± 1 -41.1 ± 0.5 10.33 ± 0.87 - 
DP5-NP 289 ± 5 -39.0 ± 1.8 10,29 ± 0.65 - 
DP10-NP 288 ± 4 -34.8 ± 0.5 10.04 ± 0.38 - 
DP30-NP 307 ± 9 -28.0 ± 1.8 3.60 ± 0.03 - 
BSA-NP 315 ± 7 -40.7 ± 0.5 13.77 ± 0.10 337 ± 15 
G-NP 317 ± 9 -27.2 ± 0.8 9.29 ± 0.09 267 ± 11 
 
Conventional nanoparticles (NP; neither cross-linked nor coated with proteins) displayed a size 
close to 280 nm, were negatively charged and the amount of RBITC incorporated in these carriers was 
calculated to be about 10 µg per mg nanoparticle (see Table 1). The cross-linkage of NP with 1,3-
diaminopropane (DP) slightly modified the size of the resulting carriers. However, the zeta potential 
significantly decreased as function of the cross-linker used to harden the carriers (from –39 mV to –29 
mV for nanoparticles cross-linked with 5 µg/mg and 30 µg/mg, respectively).  
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The coating of nanoparticles with either albumin or gelatin yielded nanoparticles with a higher size 
(around 320 nm) and a protein content of about 300 µg/mg. For G-NP, the zeta potential of these 
nanoparticles was found to be 2-fold less negative than for NP. Concerning the RBITC loading, only 
BSA-NP and DP30-NP showed a significantly different value than that obtained for conventional 
nanoparticles. For BSA-NP, the RBITC loading was about 30% higher than for NP. This is in 
consistence with Schreiber and Haimovich, who described a stronger and non-labile interaction 
between RBITC and albumin by incubation in aqueous media [28]. On the contrary, the cross-linkage 
of nanoparticles with high amounts of DP (30 µg/mg), dramatically decreased the incorporation of 
RBITC to the carriers. This fact can be due to the higher affinity of the anhydride groups of the 
copolymer to react with the cross-linker agent rather than with the isothiocyanate residues of RBITC. 
In fact, isothiocyanates can also react with carboxylic groups but need stronger conditions (i.e. acidic 
pHs) than primary amines or hydroxyl residues [29]. 
 
Studies of bioadhesion 
 
For in vivo studies, the different formulations were orally administered to laboratory animals. At 
different times, the animals were sacrificed and the gastrointestinal tract removed. Then, the gut was 
cut and divided in six regions: stomach, 4 small intestine portions (I1, I2, I3 and I4) and caecum. Each 
mucosa segment was opened lengthwise along the mesentery and rinsed with saline in order to 
eliminate the non-interacted nanoparticles. The mucosa segments, contained the adhered nanoparticle 
fractions, were digested with NaOH 3M for 24h. Finally, the fluorescent marker was extracted with 
methanol and assayed for RBITC content by spectrofluorimetry.  
These data enabled us to estimate the fraction of nanoparticles adhered to the mucosa and perform 
the profile of bioadhesion for the different formulations tested. In addition, for each formulation, the 
total adhered fraction in the whole gastrointestinal tract was plotted versus time and, from these curves, 
the parameters of bioadhesion (Qmax, AUCadh, kadh and MRTadh) estimated as described previously [30, 
31]. Qmax was defined as the maximal amount of nanoparticles adhered to the gut surface and is related 
with the capacity of the material to develop adhesive interactions. Tmax (h), is the time at which the 
particles showed the maximal adhesion within the gut. kadh was defined as the terminal elimination rate 
of the adhered fraction with the gastrointestinal mucosa. The AUCadh or the area under the curve of 
bioadhesion was evaluated by means of the trapezoidal rule up to tz, which denoted the last sampling 
point, and permitted to quantify the intensity of the bioadhesive phenomenon. Finally, MRTadh is the 
mean residence time of the adhered fraction of nanoparticles in the mucosa (estimated from time 0 to 8 
h) and evaluates the relative duration of the adhesive interactions. All of these parameters were 
calculated using the WinNonlin 1.5 software. 
 
Influence of the conformation of the copolymer on the bioadhesive properties of Gantrez nanoparticles 
 
In order to evaluate the capacity of Gantrez AN as a bioadhesive polymer, 10 mg of either an 
aqueous solution of the copolymer (Gantrez-sol) or in the form of nanoparticles (NP), were 
administered by the oral route to laboratory animals. Figure 4 shows the profile of bioadhesion for 
both formulations.  
 
Molecules 2005, 10 
 
132
Figure 4. Evolution of the adhered fraction of Gantrez in either a folded shape as 
nanoparticles or dissolved in an aqueous solution after the oral administration 
of 1 mL aqueous dispersion containing 10 mg copolymer. Each value 
represents the mean of the results of four experiments. Plot: x-axis represents 
the adhered fraction (mg); y-axis represents the different gut segments (Sto: 
stomach; I1, I2, I3, I4: small intestinal segments; Ce: caecum); z-axis 
represents the time post-administration (0.5, 1, 3 and 8 h). 
 
Sto I1 I2 I3 I4 Ce
0,5
1
3
8
0
5
10
15
20
A
dh
er
ed
 fr
ac
tio
n 
(%
 d
os
e)
NP
Sto I1 I2 I3 I4 Ce
0,5
1
3
8
0
5
10
15
20
A
dh
er
ed
 fr
ac
tio
n 
(%
 d
os
e)
Gantrez-sol
 
 
During the first three hours (after the oral administration of the different formulations), NP 
displayed a tropism for the upper areas of the gastrointestinal tract, mainly the stomach and jejunum 
(I2 segment). However, 8 h post- administration, the amount of carriers remained adhered to the gut 
appeared to be quite low and less than 5% of the given dose was found adhered to the mucosa (mainly 
in the caecum). For Gantrez-sol,  the adhered fractions were quite low and, only at 3 h post-
administration, a significant amount of nanoparticles were found adhered to the illeum (about 10% of 
the given dose). Figure 5 represents the curves of bioadhesion and the related parameters of 
bioadhesion are summarised in Table 2.  
 
Figure 5. Curves of bioadhesion for NP and Gantrez-sol, after a single oral administration of 10 mg. 
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From these results it is clear that the adhesive potential of the copolymer between methylvinyl 
ether and maleic anhydride appears to be much stronger when folded as nanoparticles than in the 
solubilised or expanded form.   
 
Table 2. Parameters of bioadhesion for NP and Gantrez-sol. 
 Qmax  
(mg) 
AUCadh  
(mg h) 
kadh  
(h-1) 
MRTadh  
(h) 
Gantrez-sol 1.53 ± 0.17 7.12 0.28 ± 0.04 3.13 
NP 3.64 ± 0.34 10.49 0.29 ± 0.03 3.41 
 
The aqueous solution of the copolymer displayed a low initial capacity to interact with the mucosa; 
although, a similar amount of RBITC was recovered in the gut mucosa 3 h post-administration. The 
maximal amounts of particles adhered to the mucosa (Qmax) were about 2.3-times higher for NP than 
for the copolymer dissolved in water. Similarly, the AUCadh significantly increased (about 1.5-times) 
when the copolymer was folded as nanoparticles. These results are in agreement with previous studies 
suggesting that the nanoparticle form would facilitate both the initial contact and the establishment of 
adhesive interactions between the pharmaceutical dosage form and the components of the mucosa [18, 
32]. However, regarding kadh and MRTadh, a similar mechanism of elimination from the mucosa 
affected both formulations. Due to the fact that conventional nanoparticles (non-coated or/and non-har
dened) are rapidly hydrolised in aqueous mediums, it is possible to speculate that nanoparticles are con
verted to the Gantrez-sol formulation and then removed from the mucosa  by the mucus-turnover mech
anism. 
 
Influence of the dose of nanoparticles on their bioadhesive properties 
 
Another interesting factor influencing the bioadhesive properties of nanoparticles and their ability 
to establish adhesive interactions with a biological support deals with the amount of carriers 
administered by the oral route. Bioadhesion of nanoparticles to rat intestinal tissue was studied by 
Durrer and co-workers [33-35]. In these works, adsorption isotherms were performed under near-
equilibrium conditions. The shape of the isotherms for poly(styrene) nanoparticles was found to be 
dependent on a particle size threshold. For nanoparticles up to 670 nm, the isotherm consisted in a 
linear increase in adsorbed amounts up to a plateau which was reached suddenly, indicating a 
saturation of the mucus layer by the particles. For poly(isobutyl cyanoacrylate) nanoparticles, the 
adsorption isotherms  showed a lower slope of the linear segments of the isotherms than for 
polystyrene latex, suggesting a lower affinity of poly(isobutyl cyanoacrylate) nanoparticles for the rat 
intestinal mucosa compared to polystyrene particles in the same size range [36, 37]. In both cases, 
isotherms had the characteristic isotherm shape of adsorbates which penetrate into a porous adsorbent. 
In this situation, the linear increase of the isotherm corresponds to the creation of new adsorption sites 
when the bulk particle concentration is increased. Those sites are available for further adsorption up to 
the isotherm plateau which corresponds to a saturation of the available sites. The possibility of a 
diffusion of particles into the mucus layer has been demonstrated by diffusion studies [38] and 
microscopy [5, 39].  
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Figure 6. Evolution of the adhered fraction of Gantrez nanoparticles as a function of the 
given dose (2.5 mg nanoparticles: NP-2.5; 5 mg: NP-5; 10 mg: NP-10 and 15 
mg: NP-15). Each value represents the mean of the results of four experiments. 
Plot: x-axis represents the adhered fraction (mg); y-axis represents the different 
gut segments (Sto: stomach; I1, I2, I3, I4: small intestinal segments; Ce: 
caecum); z-axis represents the time post-administration (0.5, 1, 3 and 8 h). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confocal microscopy studies by Scherrer et al. [39] have shown that fluorescently labelled 
poly(isobutyl cyanoacrylate) particles (211 nm in diameter) could penetrate at least 60 µm deep into 
the mucus layer of rat intestine mucosal fragments. Alternatively, 200-nm nanoparticles have been 
observed in close contact with the absorptive membrane of the gastrointestinal tract a short time after 
their oral administration to rats [5, 31]. 
Figure 6 shows the evolution of the bioadhesive profile of Gantrez nanoparticles as a function of 
the given dose. For doses lower than 10 mg nanoparticles, the profiles were quite similar with peaks of 
maximal adhesion in the stomach and in the intermediate segments of the small intestine. For the high 
dose of nanoparticles (15 mg), the maximal adhesion was found in the I2 and I3 segments (Figure 6). 
Under these conditions, it is possible to think that the mucosa would be saturated with nanoparticles 
and no more available sites were free to increase the amount of adhered particles.  
On the other hand, the study of the curves of bioadhesion (Figure 7) confirmed the influence of the 
dose of nanoparticles on their adhesion to the gut mucosa. Therefore, at low doses (NP-2.5 and NP-5), 
the curves displayed a “plateau” of adhesion for at least 3 hours followed by a slow decrease of the 
adhered amount of nanoparticles with time. On the contrary, for high doses (NP-10 and NP-15), the 
curves were characterised by an initial maximum of ahesion followed by a rapid decrease of the 
adhered amount of nanoparticles with the time (Figure 7).  
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Figure 7. Evolution of the adhered fraction of Gantrez nanoparticles in the whole 
gastrointestinal tract, after a single oral administration of 2.5 (NP-2.5), 5 
(NP-5), 10 (NP-10) or 15 mg (NP-15) nanoparticles. 
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Table 3 summarises the parameters of bioadhesion. From these results, the initial capacity to 
develop adhesive interactions within the gut (Qmax) as well as the intensity of these phenomenons 
(AUCadh) increased with the given dose. However, the elimination rate increase with the dose. In fact, 
kadh was found to be at least 3-times lower for a dose of 2.5 mg than for 15 mg nanoparticles. Similarly 
the mean residence time of the adhered fraction significantly increased by decreasing the administered 
dose: for a dose of 5 mg the MRT was found to be 1 hour longer than for 15 mg (Table 3).  
All of these results suggest that the administration of lower doses of nanoparticles appears to be a 
more efficient way to increase the percentage of the adhered fraction to the gut mucosa. In additon, it 
appears that it exists an ideal dose at which the balance between adsorption and elimination 
(desorption) is likely. For Gantrez nanoparticles this ideal dose would be close to 10 mg, because of 
the linear increase of the Qmax and AUCadh with the dose till 10 mg (Table 3). At this point, probably, a 
saturation of the binding sites within the mucosa would probably take place.  
 
Table 3. Parameters of bioadhesion for Gantrez nanoparticles as a function of the given 
dose. NP-2.5: 2.5 mg nanoparticles; NP-5: 5 mg; NP-10: 10 mg; NP-15: 15 mg. 
 
 Qmax  
(mg) 
AUCadh  
(mg h) 
kadh  
(h-1) 
MRTadh  
(h) 
NP-2.5 0.85 ± 0.11  5.16 0.16 ± 0.05 3.01 
NP-5 1.52 ± 0.41 7.10 0.09 ± 0.04 3.42 
NP-10 3.64 ± 0.34 10.49 0.29 ± 0.03 3.41 
NP-15 3.33 ± 0.61 12.38 0.45 ± 0.12 2.33 
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Influence of the cross-linking process on the bioadhesion properties of Gantrez nanoparticles 
 
When polyanhydrides (i.e. Gantrez AN) hydrolitically degrade, the product of each cleaved anhydr
ide bond is two carboxylic acid groups. In accordance with the adsorption theory of adhesion [40], car
boxylic groups would enhance the ability of polymers to form hydrogen bonds with components from t
he mucosa. Therefore, the high ability of Gantrez AN to develop adhesive interactions within the 
gastrointestinal tract may be related with the formation of carboxylic groups from the polyanhydride 
residues of the copolymer. These carboxylic groups would develop hydrogen bonds with components 
of the mucosa, such as mucins. This adhesive mechanism has been described for poly(fumaric-co-
sebacic acid) microparticles [9] and nanoparticles [41].  
 
Figure 8.  Adhered fractions of the different formulations in the different regions of the 
small gastrointestinal tract 1h (A) and 3h (B) after the oral administration of 
10 mg nanoparticles to rats. 
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Indeed, cross-linkage of PVM/MA nanoparticles with molecules containing either hydroxyl or 
amine residues (i.e. 1,3-diaminopropane) would block carboxylic groups and, therefore, stabilise the 
resulting carriers and prolong their half-life within the body.  
Figure 8 shows the gastrointestinal tract distribution of the adhered fractions of NP and cross-
linked nanoparticles 1 and 3 h post-administration to laboratory animals. All of these formulations 
displayed a similar profile of adhesion within the gut (data not shown); although the cross-linkage of 
nanoparticles with DP deceased the ability of the resulting carriers to interact with the mucosa. Thus, 
1h-post administration, close of the 25% of the given dose of NP was found adhered in the gut mucosa 
of the small intestine whereas, for DP5-NP, DP10-NP and DP30-NP, the adhered fraction was 18%, 
10% and less than 5% respectively. In addition, only for DP30-NP, a significant amount of 
nanoparticles was found in the caecum. On the other hand, 3 h post-administration, the different 
formulations displayed a more homogeneous distribution along the gut and less differences in the 
distribution of the different formulations were found. In addition, the adhered fractions of 
nanoparticles in the stomach and in the first portions of the small intestine significantly decreased, 
whereas an increase of the adhered fraction in the distal regions of the gut was found.  
 
Figure 9. Evolution of the adhered fraction of PVM/MA formulations in the whole 
gastrointestinal tract with the time, after a single oral administration of 10 mg 
nanoparticles. NP: conventional nanoparticles; D5-NP, D10-NP, D30-NP: 
cross-linked nanoparticles. 
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Figure 9 shows the evolution of the adhered fraction of nanoparticles cross-linked with DP to the 
gut mucosa of rats along the time. NP and DP-cross-linked nanoparticles displayed similar adhesive 
profile with a maximum of adhesion 30 min post-administration and a rapid decline in the adhered 
fraction over time. However the cross-linking process with the diamine decreased the adhesive 
capacity of these carriers to develop adhesive interactions with the gut mucosa (Qmax) and both the 
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intensity (AUCadh) and relative duration of the adhesive interactions (MRTadh) (see Table 4). AUCadh 
was found to be 2-fold  higher for NP than for DP30-NP. Similarly, the MRTadh was found to be 1.2 
hours longer for NP than for the cross-linked formulation.  
 
Table 4.  Parameters of bioadhesion for the different formulations tested. NP: 
conventional nanoparticles; D5-NP, D10-NP, D30-NP: cross-linked 
nanoparticles. 
 
 Qmax  
(mg) 
AUCadh  
(mg h) 
kadh  
(h-1) 
MRTadh  
(h) 
NP 3.64 ± 0.34 10.49 0.29 ± 0.03 3.41 
DP5-NP 3.43 ± 0.11 10.93 0.37 ± 0.02 3.34 
DP10-NP 2.31 ± 0.79 6.60 0.80 ± 0.08 2.31 
DP30-NP 2.24 ± 0.64 5.58 0.88 ± 0.24 2.24 
 
On the other hand, cross-linkage of nanoparticles was revealed from a significant decrease in the 
negative zeta potential, directly related to the intensity of the hardening process with DP (see Table 1). 
Higher amounts of DP yielded less negative nanoparticles, which were less efficient to establish 
adhesive interactions with the mucosa. In this context, D30-NP showed the lowest adhesive intensity 
(AUCadh) and the highest elimination rate of the adhered fraction (kadh), which may be a probe that 
hydrophobicity is a major hindrance for penetration in the mucus layer. This was also suggested by 
Durrer et al., who found that the hydrophilicity of latexes increased their adsorption to rat intestinal 
mucosa [33, 34]. Similarly, these results agree well with those obtained with gliadin nanoparticles, 
which displayed a significantly lower capacity to interact with the mucosa when particles were cross-
linked with glutaraldehyde [42].  
 
Influence of the coating agent on the gut distribution and bioadhesive properties of nanoparticles 
 
Another possibility to modify the distribution of nanoparticles within the gut may be their coating 
with different macromolecules or polymers. In this context the use of non-ionic surfactants [43] and 
polyglycerol esters of fatty acids [44] have been proposed to increase the bioadhesive capacity of 
nanoparticles.  
Similarly, a number of different scientists have been proposed the use of molecules able to target 
specific receptors within the gut, including lectins [35, 45-49], invasins [50, 51], monoclonal 
antibodies [52, 53] carbohydrates [54, 55] and vitamin B12 [56]. Thus, it has been stated that the use 
of wheat germ agglutinin (WGA)-modified nanoparticles can facilitate the binding and subsequent 
uptake of proteins due to its cytoadhesive and cytoinvasive properties [55, 56]. Similarly, the 
association between Ulex europaeus I agglutinin (UEA I; specific for α-L-fucose) and nanoparticles 
[57] or liposomes [58], can enhance their targeting to mice Peyer’s patches.  On the other hand, when 
polystyrene nanoparticles were coated with Mycoplasma gallysepticum lectin (ML), these carriers 
displayed a high tropism for the Peyer’s patches region in the small intestine [35]. 
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Similarly, the use of antibodies and proteins of immunological origin have been proposed for 
specific targeting within the gastrointestinal tract. The binding of the 5B11 monoclonal antibody (with 
specificity for rabbit M cells) to polystyrene particles, raised uptake by rabbit M-cells from 3- to 3.5-
times when compared to plain latex [52]. Another possibility for targeting a specific site in the 
gastrointestinal tract is the use of the intestinal uptake mechanism of vitamin B12 [59]. 
Despite their interest for targeting specific areas in the gastrointestinal tract, or more simply for 
intensifying the interactions with the intestinal mucosa, the development of drug delivery systems 
based on lectins, invasins or antibodies may be limited by a number of considerations [60]. These 
macromolecules may perturbate biological processes at cell membrane levels or after internalization, 
leading potentially to toxicological events. Similarly, some lectins show generally marked 
interindividual and intraindividual specificity variations [61, 62]. In addition, from a practical point of 
view, the availability on a large scale of lectins, invasins or antibodies remain difficult and expensive. 
For these reasons, the use of current excipients or dietary proteins may be a more simple and cheap 
alternative to obtain specific bioadhesive interactions within the gut.  
Figure 10 show the curves of bioadhesion for two different formulations coated with either 
albumin (BSA-NP) or gelatin (G-NP). In both cases, the curve displayed a similar shape than that of 
conventional nanoparticles; although it was clear than the coating of these particles with albumin or 
gelatin decreased the initial capacity of these carriers to interact with the gut mucosa and the intensity 
of these phenomenons (Table 5). BSA-NP displayed a more rapid elimination rate than NP; although, 
the initial capacity to develop adhesive interactions with the mucosa and the mean residence time of 
the adhered fraction were quite similar to that observed for NP. On the contrary, Qmax and AUCadh 
were 2- and 1.7-times lower, respectively, for G-NP than for NP. Similarly, the MRTadh observed for 
G-NP was found to be about 70 min lower than for NP.  
 
Figure 10.  Evolution of the adhered fraction of BSA-NP and G-NP in the whole 
gastrointestinal tract with the time, after a single oral administration of 10 
mg nanoparticles to rats.  
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Table 5. Parameters of bioadhesion for BSA-NP and G-NP. 
 
 Qmax  
(mg) 
AUCadh  
(mg h) 
kadh  
(h-1) 
MRTadh  
(h) 
NP 3.64 ± 0.34 10.49 0.29 ± 0.03 3.41 
BSA-NP 3.30 ± 0.74 8.25 0.72 ± 0.21 3.34 
G-NP 1.83 ± 0.70 6.04 0.43 ± 0.22 2.24 
 
However, the coating of Gantrez nanoparticles with either BSA or gelatin enabled us to 
dramatically modify the distribution of conventional carriers (see Figure 11).  
 
Figure 11. Evolution of the adhered fraction of 10 mg of either BSA-NP or G-NP 
dispersed in water and orally administered to rats. Each value represents the 
mean of the results of four experiments. Plot: x-axis represents the adhered 
fraction (mg); y-axis represents the different gut segments (Sto: stomach; I1, 
I2, I3, I4: small intestinal segments; Ce: caecum); z-axis represents the time 
post-administration (0.5 , 1, 3 and 8 h). 
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In fact, gelatin coated nanoparticles displayed a very low capacity to target the stomach and the 
upper regions of the gastrointestinal tract; although, these carriers were able to reach in a quite 
efficient way the jejunum and the first parts of the illeum (I2 and I3 segments). Thus, 30 min after their 
oral administration to rats, about 15% of the given dose was found in the intermediate areas of the 
small intestine. Unfortunately, G-NP appeared to lost quite rapidly their ability to reach this intestinal 
region and, 1h post-administration, the amount of nanoparticles adhered to the whole gut was quite 
low. 
On the other hand, BSA-NP displayed a high tropism for the stomach. In fact, around the 20% of 
the given dose remained adhered within the stomach for at least one hour. This fact can be related with 
the high affinity of albumin for gastric mucins, mainly in acidic mediums [63]. Similarly interesting 
was the fact that BSA-NP had any affinity for other areas of the bowel. Recently, this important 
tropism of BSA-NP for the stomach mucosa was confirmed by studying the oral bioavailability of 5-
fluorouridine. This antitumoral shows a low oral bioavailability due to a pre-systemic catabolism 
induced by different enzymes (including the P-450 system [64]) which are located in the enterocytes of 
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the small intestine, with no significant presence in the stomach and colon mucosa [64-66]. When the 
antitumoral was loaded in BSA-NP, the absolute oral bioavailability was  calculated to be 7-times 
higher than that obtained for the oral solution of the drug, 4-times higher than for 5-fluorouridine 
loaded in NP,  and 35-times higher than that obtained with nanoparticles targeting the illeum of the 
animals. Therefore, the gut distribution of these carriers in the gastrointestinal mucosa was found to be 
responsible for the significant increase in the 5-fluorouridine oral bioavailability when loaded in BSA-
NP.  
 
Conclusions 
 
Gantrez nanoparticles show a great potential as pharmaceutical dosage forms for the oral delivery 
of hydrophilic molecules, including antigens, proteins and peptides. The analysis of the adhesion 
curves (cumulative amount of adhered particles in the whole gut vs. time) permits to estimate the 
bioadhesive potential of a given drug delivery system and make easy comparisons between different 
concentrations of the same formulation. The cross-linkage and / or coating of these nanoparticles  
permits to modulate their transit and bioadhesive properties (intensity, extent, duration and, sometimes, 
location). In this context, the use of BSA to coat Gantrez nanoparticles enabled us to develop drug 
carriers with a high tropism for the stomach mucosa. 
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